Skip to main content
. 2012 Feb 13;209(2):395–406. doi: 10.1084/jem.20110216

Figure 5.

Figure 5.

Inhibition of PI3K leads to expression of Ikaros and to μHC generation. (A) Immunoblot analysis of FoxO1, Ikaros, and μHC expression in Pten-deficient cells treated with either DMSO or the PI3K inhibitor LY294002. Immunoblotting for actin served as loading control. (B) Flow cytometric analysis of µHC expression in Pten-deficient cells treated with either DMSO or the PI3K inhibitor LY294002. (C) Flow cytometric analysis for µHC and GFP expression of Pten-deficient cells transduced with an EV or an expression vector encoding dominant-negative Ikaros (IK6) and treated with LY294002. (D) Immunoblot analysis for Ikaros expression in SLP-65–deficient pre–B cells treated with DMSO or the PI3K inhibitor LY294002. Immunoblotting for actin served as loading control. (E) Immunoblot analysis for Ikaros expression in SLP-65–deficient pre–B cells transduced with 4-hydroxytamoxifen (4-OHT)–inducible forms of either SLP-65 (ERT2-SLP65) or FoxO1-A3 (ERT2-FoxO1-A3). Upon sorting of positively transduced cells, the cells were treated with the solvent ethanol (−) or 4-OHT (+) to activate ERT2-SLP65 and ERT2-FoxO1-A3. Immunoblotting for actin served as loading control. (F) Top, FACS plots for κLC expression in SLP-65–deficient pre–B cells transduced with an EV or with an Ikaros expression vector. Cells were cultured in the presence of IL-7. Bottom, dot plots for κLC expression in SLP-65–deficient pre–B cells transduced with an EV or with an expression vector for DN-Ikaros (IK6); both were treated with the PI3K inhibitor LY294002. Numbers in quadrants indicate percentages of cells in the respective region. Data are representative of at least two to three independent experiments.

HHS Vulnerability Disclosure